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Ralph Steinman: Dendritic cells bring home the Lasker
Ralph Steinman is perhaps best known as a codiscoverer of dendritic cells 
(DCs) and as a founding father of the research area that these cells have 
spawned. For his discovery, Steinman was recently awarded the 2007 Albert 
Lasker Award for Basic Medical Research. Yet the man behind the research 
holds his praise for the many other scientists—in the U.S. and abroad—who 
have further advanced the therapeutic promise of DCs.
A successful battle against a foreign 
antigen is the outcome of a precise 
series of events—the outsider must be 
recognized, captured, and delivered to 
just the right group of immune cells. 
At the same time, the immune system 
must be prevented from reacting to its 
own antigens. More than three decades 
after the discovery of DCs, it is now 
clear that these cells are equipped to 
handle both tasks. DCs can sample 
antigens anywhere in the body, deliver 
the information to lymphoid organs, 
and activate different types of lympho-
cytes depending on the job at hand—
defense versus tolerance. DCs are now 
being used to enhance resistance to 
pathogens and cancers and to treat 
allergies and autoimmune disorders. 
Ralph Steinman may be credited with 
the discovery of this unique cell type, 
but he is quick to share the accolades 
with his colleagues.
Career change
Steinman was a physician at Massachusetts 
General Hospital (Boston, MA) in 
1968 when his interest in immunology 
was first piqued by a lecture series on 
“new cellular immunology.” Macfarlane 
Burnet’s clonal selection theory, which 
proposed that every antigen is recog-
nized by a single, clonal immune cell, 
was then about a decade old and had 
become the bedrock of immunology. 
B and T cells had been identified as 
the perpetuators of antibody- and cell-
mediated immunity, respectively, and 
their mechanisms were being rapidly 
uncovered. These discoveries and their 
potential impact on clinical practices 
appealed to Steinman. But despite all 
the advances in understanding the 
immune system since Burnet’s time, 
Steinman notes, one fundamental 
question remained unanswered: “We 
still didn’t know how an immune re-
sponse got started.”
As a physician, Steinman had first-
hand experience with this mystery. 
The immune systems of tuberculosis 
patients and of healthy humans who 
had been vaccinated with the tuber-
culosis vaccine “recognized” the 
bacterial antigens in skin tests. Those 
who had never been exposed to the 
bug did not. “We had the beautiful 
clonal selection theory, which pro-
posed that a preexisting clone would 
recognize and respond to any antigen 
that comes along,” says Steinman. 
“But there was this big glaring gap 
where, in some instances, a foreign 
antigen was simply not inducing a 
response [in nonexposed individuals].”
To understand how antigens prompt 
immune reactions, Steinman began 
postdoctoral work in the laboratory of 
Zanvil Cohn at Rockefeller University. 
Cohn was a pioneer in the study of 
macrophages and their role in taking 
in and breaking down proteins and 
infectious agents. In this lab, Steinman 
began by studying how macrophages 
captured and presented soluble antigens 
to initiate an immune response.
“The macrophage was regarded as 
a good system to study immune re-
sponse initiation,” says Steinman, 
“because they were thought to pres-
ent intact antigen.” But he found that 
the macrophages didn’t present whole 
antigen; they simply degraded it (1). 
Steinman decided he’d better look 
beyond these cells.
A new cell makes its mark
Leaving macrophages behind, Steinman 
turned to a mixture of cells from the 
mouse spleen. Suspensions of cells from 
this organ, which is one of the sites 
where immune responses get started, 
had been recently shown to induce 
antibody responses against sheep red 
blood cells (2). This was the first in 
vitro demonstration of a primary anti-
body response. But lymphocytes purified 
from the spleen could not bring about 
these responses unless they were min-
gled with a population of so-called 
“accessory” cells, a portion of which 
were macrophages.
This finding prompted Steinman 
to perform a very simple experiment. 
“I did something that evidently had 
not been done before,” he says. He 
looked at these accessory cells in the 
culture dish. Thanks to his newly ac-
quired skills in phase–contrast light 
microscopy, Steinman experienced a 
“Eureka!” moment. He found, mixed 
in with the macrophages, star-shaped 
cells unlike any immune cell seen before. 
When they crawled, the newcomers 
extended and retracted their radial 
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branches. Since they were not phago-
cytic, they were lighter than macro-
phages on density gradients. As a result, 
recalls Steinman, “we could separate 
them cleanly from macrophages, even 
though this was before the days of 
monoclonal antibodies.”
These cells were not just a culture 
dish artifact; Steinman found them in 
mouse peripheral lymphoid organs. 
And unlike the more populous macro-
phages, these cells did not take up 
antigens. Steinman and Cohn were 
convinced that a new cell type had 
arrived in the immune world—they 
christened them dendritic cells and 
described their physical and physiological 
features in two papers in the Journal of 
Experimental Medicine (3, 4).
Form finds function
The papers generated a spirited debate 
about whether these cells were a new 
class of white blood cells or merely an 
artifact. Many opponents thought they 
were too rare to make a difference. 
For believer Steinman, however, the 
next step was to test whether the DCs 
were the missing link between recog-
nition and immune response. He de-
signed a protocol to purify DCs from 
mouse spleen fractions that Michel 
Nussenzweig, one of Steinman’s first 
graduate students, calls “a cumber-
some, onerous task” that yielded only 
a tiny number of DCs. Nussenzweig 
made the enrichment process easier 
when he developed a DC-specific an-
tibody a few years later (5). Wesley 
Van Voorhis, another graduate student, 
later used the same protocol to isolate 
DCs from human blood (6).
Using the enriched population, 
Steinman found that these cells ex-
pressed very high levels of a surface 
antigen called MHC class II, which 
was later shown to be an antigen-
presenting molecule. Steinman tested 
whether DCs might be better than 
known antigen-presenting cells 
(APCs) at initiating immune responses. 
He and his then technician, Maggi 
Pack, added DCs or known APCs to 
a mixture of lymphocytes from two 
different donors—an assay known as a 
mixed leukocyte reaction (MLR). 
They found that the DCs were an 
impressive 100-fold better at activating 
T cells in the mix than were macro-
phages or B cells (7). “I was shocked 
by the numbers,” says Pack, “but 
Ralph had already moved on to de-
signing the next experiment.” Van 
Voorhis found that the same was true 
for human DCs. “We presented our 
findings at a FASEB meeting and an-
gered a lot of people,” he recalls. 
“They were so attached to the idea 
that human monocytes were the best 
antigen presenters.”
The assay proved that DCs pre-
sented their own antigens to T cells. 
But to prove that DCs were relevant 
physiologically, the team had to show 
that DCs could pick up external anti-
gens, process and present them, and 
thereby activate lymphocytes. To do 
so, Nussenzweig coated one set of cells 
with antigen. He then added these cells 
to a mixture of DCs or other APCs. 
Only the DCs captured the antigen and 
presented it to T cells, which then 
became cytotoxic. This was the first 
demonstration that DCs could prompt 
CD8+ T cell–mediated immunity (8).
Kayo Inaba, a postdoc who had just 
arrived in the lab, showed that DCs also 
induced the development of CD4, 
“helper” T cells that then initiated po-
tent antibody responses (9). DCs were 
now emerging as the command center 
“I was shocked by the numbers,” 
says Maggi Pack, “but Ralph 
had already moved on to designing 
the next experiment.”
A phase–contrast image shows a dendritic cell.
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of the immune response operation. But 
Steinman admits, “we were still think-
ing of DCs only as cells that instigated 
a primary immune response. What we 
didn’t appreciate was that there were 
many different facets of the immune 
response that DCs could control.”
DCs go global
DCs had so far been identified in the 
spleen and in the T cell areas of Peyers 
patches. A good deal of this work had 
been done in Steinman’s lab in New 
York. But around 1980, DCs began to 
make their international debut. Robert 
Lechler and Richard Batchelor at Ham-
mersmith Hospital (London) recapitu-
lated Nussenzweig’s MLR experiment 
in vivo by showing that DCs injected 
into rats induced the rejection of for-
eign kidney grafts (10).
The DCs also began to show up 
in other areas of the immune system, 
including the lymph system. The 
identification of DCs in rabbit and rat 
lymph vessels, by Brigette Balfour, 
Gordon MacPhearson, Stella Knight, 
and others in England, and Hemmo 
Drexhage in the Netherlands, intro-
duced the idea that these cells were a 
roving surveillance network (11, 12). 
Steinman proposed that DCs were 
picking up antigen in peripheral tis-
sues and then migrating to lymphoid 
organs to start the immune response. 
This idea would explain why immune 
responses could also begin in the 
draining lymph nodes nearest the site 
of antigen deposition.
To test the idea, Steinman’s team 
began to look for DCs in peripheral 
tissues. Austrian scientists Gerold 
Schuler and Nikolaus Romani, who 
had been studying antigen presenta-
tion in the skin, arrived in Steinman’s 
lab to investigate whether skin Lang-
erhans cells (LCs) were a form of 
DCs. The duo proved this link and 
made a second tantalizing discovery: 
DC maturation. Schuler found that 
LCs could pick up antigen but did not 
stimulate T cells unless they were first 
cultured with the cytokine GM-CSF 
(13). Romani found that the GM-
CSF–“matured” cells could no longer 
capture anti  gen but were adept at 
stimulating T cells (14). Antigen cap-
ture was thus distinguished from im-
mune responsiveness.
Building up the DCs
The biggest hurdle to DC research 
thus far was their limited availabil-
ity—monoclonal antibodies and cell 
sorters easily sifted DCs from tissue 
suspensions, but DCs were a relatively 
rare population to begin with. “People 
weren’t even convinced that these 
were cells with a separate pathway of 
differentiation,” recalls Steinman. 
“Most people weren’t making DCs to 
test them,” he says. “Only those who 
took the trouble were impressed by 
their potency.”
But in the early 1990s, three 
teams, including Steinman’s group, 
grew DCs from different sources. 
Steinman and his team discovered 
that DCs could be grown from 
GM-CSF–treated blood and bone 
marrow progenitor cells. Teams led 
by Jacques Banchereau at Schering 
Plough in France and Antonio Lanza-
vecchia at the Basel Institute in Swit-
zerland found that DCs could be 
grown from CD34+ hematopoeitic 
progenitor cells from humans and 
differentiated from human blood 
monocytes (15–17).
Enhancement versus tolerance
With DCs now readily available, Stein-
man began to test their mettle in vivo. 
Immature DCs that were cultured with 
antigens and injected into mice jump-
started immune responses without help 
from adjuvants such as alum or Freund’s 
(18). Steinman dubbed these cells 
“nature’s adjuvants.”
Other groups started to exploit this 
adjuvant-like nature of DCs to boost the 
immune systems of cancer patients. 
Monocytes were extracted from patients, 
differentiated into DCs, and loaded with 
tumor antigens. When these DC 
“vaccines” were reinfused into patients, 
some tumors were destroyed. But the 
failure of injected DCs to migrate prop-
erly and establish themselves in lymphoid 
tissues prevented this approach from 
being more successful.
Madhav Dhodapkar, a Rockefeller 
scientist who is using DCs to boost 
human immunity to multiple myeloma 
tumors, benefits regularly from Stein-
man’s input. “He’s such a great supporter 
of human work,” says Dhodapkar. But 
he cautions that this research area is still 
very much in its early stages. “Many 
groups have shown that this approach 
has immune efficacy and can be carried 
out safely. But it is still an evolving 
science, and there is a lot left to do to 
optimize this process.”
Steinman’s response 
to all the theorizing: 
“Just do the experiment!”
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Steinman himself is less than 
pleased with the speed with which 
this line of work has evolved. “This 
idea [of DC immunotherapy] has 
progressed very slowly,” he laments, 
“even though immunology clearly 
needs to be explored in depth to help 
cancer patients.” He blames poor 
funding and badly coordinated stud-
ies for the slow progress of DCs from 
the lab bench to the intravenous 
drip.
A decade after DCs were identi-
fied as powerful immune enhancers, 
Steinman and Nussenzweig—now 
also a faculty member at Rocke-
feller—added a new twist to the DC 
tale. They found that when antigens 
were captured by DCs that were un-
altered either by culturing or inflam-
mation, the DCs killed T cells instead 
of activating them, thus establishing 
tolerance (19). Inaba, who continues 
to collaborate with Steinman, simul-
taneously showed that immature DCs 
that corral dying infected cells also 
fail to activate T cells and induce tol-
erance (20). Steinman’s group later 
found that DCs also induced the ex-
pansion of regulatory T cells (21). 
This work suggests that the DC net-
work is wired to steer the body away 
from self-reactivity when danger is 
absent.
The CDs of DCs
For Steinman, the question of how an-
tigens are delivered to start an immune 
response has evolved into how DCs 
control the quality of the immune re-
sponse. He and his group are currently 
trying to target antigens directly to the 
DC receptors that take them in—a 
process shown to enhance immunity. 
CD205 (also known as DEC-205) is 
the primary antigen-binding receptor 
in many DC subsets. Coupling an anti-
CD205 monoclonal antibody to an an-
tigen increases the antigen’s presentation 
by  100 fold (22).
Steinman also wonders how matu-
ration signals tweak the DCs to modify 
immune responses, for example, to 
guide the development of T helper 
(Th)-cells into Th1 or Th2 subsets. 
“We need to understand what infor-
mation a T cell needs to receive from 
a DC before it starts responding along 
a particular path,” he says. As DCs vary 
their expression of costimulatory re-
ceptors such as CD40, CD70, and 
CD80/86 depending on the matura-
tion stimuli, the strength and quality of 
the stimulation signal they impart 
probably help determine the function 
of the responding cell.
Ending credits
Steinman credits the progress and in-
terest that DC biology has enjoyed to 
fellow DC enthusiasts in his own lab 
and around the globe, endearing him 
to his coworkers and peers. Says for-
mer graduate student Josh Metlay, 
“Ralph’s way of pursuing an idea was 
not to put one step in front of another; 
he liked to get people to approach the 
same problem from different angles.” 
Others recall his eagerness to get to the 
scientific task at hand when ideas were 
bandied about during lab meetings. 
Steinman’s response to all the theorizing: 
“Just do the experiment!”
Ralph Steinman’s research career, 
which began with finding a new cell, 
resulted in the founding of an entire 
research field. His colleagues in the 
early years recount the uphill task he 
faced. “Ralph was the lone voice in 
the desert,” says Van Voorhis. “It 
took almost ten years for people to 
accept that DCs and their immune 
potency were for real. But history 
proved him right.”
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“It took almost ten years for people 
to accept that DCs and their 
immune potency were for real. 
But history proved [Steinman] right.”
— Wesley Van Voorhis
MHC class II proteins (red) inside immature 
Langerhans cells (green) are expressed on 
the surface when the cells mature (bottom).
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